Neurogene’s (NGNE) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Neurogene (NASDAQ:NGNE) in a report issued on Tuesday,Benzinga reports. They currently have a $55.00 price objective on the stock. HC Wainwright also issued estimates for Neurogene’s Q4 2024 earnings at ($1.05) EPS, FY2024 earnings at ($4.34) EPS, Q1 2025 earnings at ($0.77) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.83) EPS and FY2025 earnings at ($3.19) EPS.

A number of other research firms also recently weighed in on NGNE. BMO Capital Markets reduced their target price on Neurogene from $65.00 to $60.00 and set an “outperform” rating on the stock in a report on Tuesday, November 12th. Robert W. Baird boosted their target price on shares of Neurogene from $54.00 to $72.00 and gave the company an “outperform” rating in a report on Tuesday, November 12th. Leerink Partners increased their price target on shares of Neurogene from $45.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 12th. Finally, Stifel Nicolaus boosted their price objective on shares of Neurogene from $44.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, November 12th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Neurogene has an average rating of “Buy” and a consensus price target of $60.83.

Neurogene Stock Up 1.7 %

NASDAQ:NGNE opened at $15.59 on Tuesday. Neurogene has a 12 month low of $12.49 and a 12 month high of $74.49. The company has a 50-day moving average price of $45.41 and a 200-day moving average price of $39.62.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quest Partners LLC purchased a new position in Neurogene in the 2nd quarter worth approximately $55,000. BNP Paribas Financial Markets increased its holdings in shares of Neurogene by 192.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock worth $91,000 after purchasing an additional 1,429 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Neurogene during the first quarter valued at $120,000. MetLife Investment Management LLC purchased a new stake in shares of Neurogene during the third quarter valued at $254,000. Finally, Jane Street Group LLC bought a new stake in Neurogene in the 3rd quarter worth about $324,000. Institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.